We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
We are featuring 16 research reports from our analyst team in today's Zacks Research Daily, including reports on Gilead (GILD - Free Report) , Altria (MO - Free Report) , Qualcomm QCOM and Pfizer PFE.
Gilead shares have turned around a bit in recent days, but still still lag the broader market in the year-to-date period on continued negative sentiment on the biotech space as a whole. These clouds notwithstanding, the covering analyst likes this Zacks Rank # 2 (Buy) rated stock for its strong HIV and HCV portfolio and robust product pipeline, which could get further boost from deals that the company has plenty of financial firepower to execute. (You can read the full research report on GLD here.)
Zacks Rank # 2 (Buy) rated Altria shares are up an impressive +19% year-to-date, likely reflecting the low-beta tobacco giant's stable business outlook and attractive dividend (currently yielding a juicy 3.2%). The analyst likes the company's strong portfolio of tobacco and wine products and its ability to adapt to evolving demands, such as developing several non combustible tobacco products. (You can read the full research report on MO here.)
The analyst likes the buy-rated Qualcomm stock for its leadership position in the global wireless baseband chipset market and its growing presence in related opportunities such as mobile computing and IoT. The company's new patent license agreements with Chinese smartphone makers should boost Qualcomm’s top line and also solidify its footing in the Chinese market (You can read the full research report on QCOM here.)
Other noteworthy reports we are featuring today include Procter & Gamble (PG - Free Report) , Novartis (NVS - Free Report) and Southern Company (SO - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles includeEarnings TrendsandEarnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios. If you want an email notification each time Sheraz publishes a new article, pleaseclick here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top 7 Research Reports for July 11, 2016
Monday, July 11, 2016
We are featuring 16 research reports from our analyst team in today's Zacks Research Daily, including reports on Gilead (GILD - Free Report) , Altria (MO - Free Report) , Qualcomm QCOM and Pfizer PFE.
Gilead shares have turned around a bit in recent days, but still still lag the broader market in the year-to-date period on continued negative sentiment on the biotech space as a whole. These clouds notwithstanding, the covering analyst likes this Zacks Rank # 2 (Buy) rated stock for its strong HIV and HCV portfolio and robust product pipeline, which could get further boost from deals that the company has plenty of financial firepower to execute. (You can read the full research report on GLD here.)
Zacks Rank # 2 (Buy) rated Altria shares are up an impressive +19% year-to-date, likely reflecting the low-beta tobacco giant's stable business outlook and attractive dividend (currently yielding a juicy 3.2%). The analyst likes the company's strong portfolio of tobacco and wine products and its ability to adapt to evolving demands, such as developing several non combustible tobacco products. (You can read the full research report on MO here.)
The analyst likes the buy-rated Qualcomm stock for its leadership position in the global wireless baseband chipset market and its growing presence in related opportunities such as mobile computing and IoT. The company's new patent license agreements with Chinese smartphone makers should boost Qualcomm’s top line and also solidify its footing in the Chinese market (You can read the full research report on QCOM here.)
Other noteworthy reports we are featuring today include Procter & Gamble (PG - Free Report) , Novartis (NVS - Free Report) and Southern Company (SO - Free Report) .
You can find all of today's stock research reports here.
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios. If you want an email notification each time Sheraz publishes a new article, please click here.